Clinical Proteomics operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Manuscripts will be assigned to a handling Editor, who will appoint at least two referees. On receipt of their reports the handling Editor will make a recommendation to accept, to accept with minor revisions, to request major revisions and resubmission, or to reject. No manuscript will be rejected without being assessed by a member of the Editorial Board and one other expert.
Clinical Proteomics considers the following types of article: Letter to the Editor, Meeting report, Research, and Review. For more specific information, please take a look at our Submission Guidelines.
Clinical Proteomics is affiliated with the Human Proteome Organization (HUPO). HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
- Editorial Board
- Sign up for article alerts and news from this journal
2017 Journal Metrics
72.6 days to first decision for reviewed manuscripts only
63.6 days to first decision for all manuscripts
147.2 days from submission to acceptance
12.8 days from acceptance to publication
43 Altmetric mentions